Kevin M Flanigan

Proof of Concept of the Ability of the Kinect to Quantify Upper Extremity Function in Dystrophinopathy

Lise Worthen-Chaudhari, Linda P Lowes, Lindsay N Alfano, 2013, PLoS currents.

Expression profiling of FSHD muscle supports a defect in specific stages of myogenic differentiation.

Kevin M Flanigan, S. Tapscott, K. Flanigan, 2003, Human molecular genetics.

Spinocerebellar ataxia type 31 is associated with "inserted" penta-nucleotide repeats containing (TGGAA)n.

Yuko Saito, Mari Yoshida, Fumitoshi Ishino, 2009, American journal of human genetics.

The TREAT-NMD DMD Global Database: Analysis of More than 7,000 Duchenne Muscular Dystrophy Mutations

Christophe Béroud, Hanns Lochmüller, Petr Brabec, 2015, Human mutation.

Readthrough of dystrophin stop codon mutations induced by aminoglycosides

Uwe Fass, Kevin M Flanigan, C. Anderson, 2004, Annals of neurology.

A phase 1/2a follistatin gene therapy trial for becker muscular dystrophy.

Eric Meadows, Sarah Lewis, Linda P Lowes, 2015, Molecular therapy : the journal of the American Society of Gene Therapy.

The Muscular Dystrophies

Kevin M Flanigan, K. Flanigan, 1999, Seminars in Neurology.

The TREAT‐NMD Duchenne Muscular Dystrophy Registries: Conception, Design, and Utilization by Industry and Academia

Domenica Taruscio, Emma Heslop, Jes Rahbek, 2013, Human mutation.

LTBP4 genotype predicts age of ambulatory loss in duchenne muscular dystrophy

Craig McDonald, Kevin M Flanigan, Jerry R Mendell, 2013, Annals of neurology.